Lenalidomide and checkpoint inhibitors improve response to BsAbs. Lymph node–derived lymphocytes were incubated without (w/o) or with 2 concentrations (C2, C3) of CD19-BsAb (C3 ≙ “Low,” C2 ≙ “High”) or 1 concentration of CD20-BsAb (C3 ≙ “Low”) and/or 1 combination drug as indicated. Cells were harvested after 7 days and analyzed by using quantitative flow cytometry. Box plots show the percentages of the absolute numbers of viable B cells (A, C, D) or the x-fold expansion of viable T cells (B). The blue (panel A, B cells) and red (panel B, T cells) solid lines connect the medians of each condition to ease interpretation. Shown are data from n = 27 (low concentration of CD19-BsAb) or n = 13 (high concentration of CD19-BsAb) or n = 24 (low concentration of CD20-BsAb) biologically independent samples. (C and D) Data were separated by the response groups, as defined in Figure 2H. Conditions were tested for significance either as indicated by the brackets (panels A and B) or between the 2 response groups (panels C and D) by using the paired (panels A and B) or unpaired (panels C and D) two-sided Wilcoxon’s test. P values were corrected for multiple testing by using the Benjamini-Hochberg procedure. *** ≙ P ≤ .001; ** ≙ P ≤ .01; * ≙ P ≤ .05; ns ≙ P > .05. ns, not significant.